Cannabis Moves to Schedule III — With Major Caveats
On April 23, 2026, Acting Attorney General Todd Blanche signed an order immediately placing two categories of cannabis into Schedule III of the Controlled Substances Act: marijuana products regulated by a qualifying state medical cannabis license, and FDA-approved drug products containing marijuana (currently led by Epidiolex). The move follows President Trump’s December 18, 2025 Executive Order directing the DOJ to expedite rescheduling.
This is the most significant federal cannabis policy shift in more than fifty years. But it is important to be precise about what changed and what did not. Non-medical cannabis remains firmly in Schedule I, alongside heroin and LSD. Recreational cannabis, unlicensed products, and synthetically derived THC are all still Schedule I. The order explicitly states that any marijuana outside those two categories “remains a schedule I controlled substance.” Federal prohibition has not ended. What has changed is the federal government’s recognition that state-licensed medical cannabis has accepted medical value, a premise that paves the way for further reform.
“It is the biggest thing that has happened in decades of federal cannabis policy. I think this is a force multiplier.” — Brian Vicente, founding partner, Vicente LLP
According to analysis released jointly by Vicente LLP and the Minority Cannabis Business Association, the resulting reform of IRS tax code Section 280E is projected to create 55,000 jobs by 2030, generating up to $2.7 billion in wages and $5.6 billion in new economic activity. Those figures are projections, but they underscore the scale of what the tax relief alone could mean for the industry.
Key Tax Implication: 280E Relief
Section 280E of the IRS code barred cannabis businesses from deducting ordinary business expenses, resulting in effective federal tax rates of roughly 70 to 80 percent for medical dispensaries. Under Schedule III, qualifying businesses can now deduct rent, payroll, and other standard business costs. The Cannabis Regulators Association estimates effective rates could fall to approximately 20 to 30 percent, measured from the April 23, 2026 effective date. Whitney Economics estimates cannabis businesses paid approximately $15 billion in excess 280E-related federal taxes since 2018.
A broader DEA administrative hearing to consider rescheduling all cannabis, including adult-use, is scheduled to begin June 29, 2026, and is expected to conclude by July 15. Interested parties seeking to participate must file a written notice of intention by 11:59 PM ET on May 24, 2026. A final rule from that hearing, if it proceeds on schedule, could be published as soon as late 2026, though litigation could extend that horizon considerably. Smart Approaches to Marijuana has publicly announced plans to challenge the current rescheduling order.
Sources
- Marijuana Moment: Federal Marijuana Rescheduling Announced by DOJ
- DOJ Official Press Release, April 23, 2026
- Vicente LLP: DOJ Issues Final Order Rescheduling Medical Cannabis to Schedule III
- Foley Hoag: DOJ Immediately Reschedules State-Licensed Medical Cannabis
- Vicente LLP: Cannabis Rescheduling Explained (Resource Hub)
State Dispensary DEA Registration: 60-Day Window Now Open
One of the most actionable immediate consequences of rescheduling is a 60-day window for state-licensed medical cannabis businesses to file for federal DEA registration. The DEA’s Medical Marijuana Dispensary Registration Portal went live on April 30, 2026. That window closes June 22, 2026.
Dispensaries must apply using DEA Form 224 and provide detailed information about storage, ordering, dispensing procedures, inventory management, suppliers, and individuals with access to controlled substances. There is an annual $794 application fee. The existing state medical recommendation or certification model is preserved, meaning patients will not need a traditional federal prescription and dispensaries will not need to convert into pharmacies.
Deadline: June 22, 2026
State-licensed medical cannabis businesses have until June 22, 2026 to file for DEA registration and access Schedule III legal protections. This deadline has received significantly less media attention than the 280E tax story. Businesses that miss the window will not be automatically protected during the review period.
Sources
- Marijuana Moment: DEA Will Start Accepting Applications This Week
- Marijuana Moment: State-Licensed Marijuana Businesses Can Now Apply
- HealthDataConsortium: Marijuana Rescheduling 2026 — Order, Deadlines, What Changed
Medicare Coverage for CBD: A Pilot Program Begins
Announced alongside the December 18, 2025 Executive Order, a Medicare CBD pilot program is now underway. Dr. Mehmet Oz, administrator of the Centers for Medicare and Medicaid Services (CMS), announced a model allowing eligible Medicare and Medicaid beneficiaries to access hemp-derived CBD under doctor recommendation at no cost, up to a certain threshold. The Commonwealth Project estimates 8,000 to 12,000 patients will participate, with projected annual savings of up to $64 billion through improved symptom management and reduced reliance on certain high-cost interventions.
The program is partnering with Charlotte’s Web and covers conditions including cancer-related pain. While coverage for flower and vape products remains years away pending additional FDA approvals, this represents the federal government’s first-ever step toward health insurance coverage for cannabis-derived products. Coverage is limited to hemp-derived CBD with up to 3 mg of THC per serving within participating Accountable Care Organizations and oncology programs.
A note of important context: the CMS had previously published a 2026 final rule stipulating that cannabis and CBD were ineligible for Medicare Advantage coverage. That rule was revised ahead of the executive order. The policy landscape on insurance coverage continues to evolve, and readers should consult their own healthcare providers for specifics.
Sources
- Marijuana Moment: Federal Health Programs Will Cover Up to $500 Worth of CBD
- Marijuana Moment: Trump Signs Executive Order to Reclassify Marijuana
ATF Gun Form Updated to Recognize Medical Marijuana’s Legal Status
In a development published by Marijuana Moment, the Bureau of Alcohol, Tobacco, Firearms and Explosives is proposing to update its gun purchase Form 4473 to reflect medical marijuana’s new federal legal status under rescheduling. For years, the form has included a question asking whether the buyer unlawfully uses cannabis, accompanied by a warning that cannabis use “remains unlawful under Federal law regardless of whether it has been legalized or decriminalized for medicinal or recreational purposes.” Under the proposed revised form, that language is gone. Instead, buyers would attest that they are not an unlawful user of any controlled substance, with a warning specifying only that “Federal law does not permit the use or possession of marijuana for recreational purposes.” The omission of medical cannabis from the prohibition language is a direct acknowledgment that state-licensed medical patients now occupy different legal ground under Schedule III.
The picture on gun rights more broadly remains complicated. Acting Attorney General Blanche has signaled the administration is reviewing its defense of the federal law that bars cannabis consumers from owning firearms case by case, but the Trump DOJ argued as recently as March before the U.S. Supreme Court that the ban is constitutional in the case U.S. v. Hemani. The Solicitor General also sent the Supreme Court a letter saying rescheduling should not affect the court’s decision in that case. ATF is accepting public comments on the revised Form 4473 through July 7, and a separate interim ATF rule narrowing the definition of “unlawful user” of controlled substances is open for comment through June 30.
Action: Comment Period Open Through July 7
ATF is accepting public comments on the proposed revised Form 4473 through July 7, 2026. Industry stakeholders, patients, and Second Amendment advocates all have an interest in the final language. The proposed form and comment instructions are available through the Federal Register.
Sources